FDA approves Xocova for COVID-19 postexposure prophylaxis
The U.S. Food and Drug Administration has approved Shionogi's Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older.
Jun 9, 2026
0
18









